Pharmacy Screening Demonstrates Great Efficiency and Potential for Cost Reductions

A new publication by Boots UK and ScreenCancer highlights the benefits of ScreenCancer’s Mole Scanning Service in the pharmacy setting. The service evaluation has shown that the service, which offers customers the opportunity to have worrying skin lesions assessed by consultant dermatologists on a drop-in basis within community pharmacies, is effective at triaging patients and ultimately playing a part in identifying diagnoses of malignant melanoma. The study estimates that up to GBP 10m could be saved annually in the UK from avoided GP consultations if extending the service sufficiently to provide national coverage, not including additional benefits of additional measures of increasing awareness and prevention measures, and earlier diagnosis. The study also estimates that a further GBP 1.3m could be saved by allowing pharmacists to refer patients with suspicious lesions directly to dermatologists in secondary care.


More information about the publication can be found here:

March 30, 2021

New Head of Product at DeepX Health

Read more

March 15, 2021

DeepX Health selected to present at Nordic Life Science Days

Read more

October 23, 2020

Primary Care Setting Pilot Launched with NHS

Read more

October 14, 2020

DeepX Health to Present at the 8th World Congress of Teledermatology, Imaging and Artificial Intelligence for Skin Diseases

Read more

September 30, 2020

ScreenCancer Awarded Support for Diagnostic Triage Algorithm-Project

Read more

January 8, 2020

DeepX Health to participate at the 7th Annual Dermatology Summit in San Francisco

Read more

December 13, 2019

DeepX Health to present at Digital Health World Congress in London

Read more

December 3, 2019

DeepX Health participate in the DxPx Conference

Read more

December 1, 2019

ScreenCancer approved for first round of Horizon 2020 programme

Read more